Thrombin - Angiotech Pharmaceuticals

Drug Profile

Thrombin - Angiotech Pharmaceuticals

Alternative Names: Hemaseel Thrombin; Human thrombin - Haemacure; Thrombin hemostat

Latest Information Update: 19 Jul 2012

Price : $50

At a glance

  • Originator Haemacure Corporation
  • Developer Angiotech Pharmaceuticals
  • Class Antifibrinolytics; Antihaemorrhagics; Blood coagulation factors; Coagulants; Serine endopeptidases
  • Mechanism of Action Thrombin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Haemorrhage

Most Recent Events

  • 29 Mar 2012 Suspended - Preclinical for Haemorrhage in Canada (Topical)
  • 07 Apr 2010 Angiotech Pharmaceuticals acquires certain assets of Haemacure Corporation, including its thrombin product
  • 19 Aug 2009 Preclinical development is ongoing in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top